Back to Journals » OncoTargets and Therapy » Volume 7

Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence

Authors Jackson M, Rusthoven C, Fisher C, Schefter T

Received 24 February 2014

Accepted for publication 6 April 2014

Published 16 May 2014 Volume 2014:7 Pages 751—759


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Matthew W Jackson, Chad G Rusthoven, Christine M Fisher, Tracey E Schefter

Department of Radiation Oncology, University of Colorado, Denver, CO, USA

Abstract: The addition of bevacizumab to established therapies for metastatic and locally advanced cervical cancer is an area of evolving research and a potential strategy toward improving historically suboptimal outcomes for women with advanced disease. Bevacizumab, when added to first-line chemotherapy, has now been shown to improve overall survival among women with metastatic cervical cancer, and recent Phase II data suggests it is safe and effective for patients with locally advanced disease treated with curative intent. Here we review the rationale and current evidence for bevacizumab in clinical practice, with an emphasis on the emerging role of bevacizumab in the treatment of metastatic and locally advanced cervical cancer.

Keywords: bevacizumab, Avastin®, advanced cervical cancer, metastatic cervical cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]